Category Press Releases

Spruce Biosciences Reports Positive FDA Meetings and Advances TA-ERT BLA Submission for Q4 2026

Spruce Biosciences Advances Toward 2026 BLA Submission for Tralesinidase Alfa in Sanfilippo Syndrome Type B Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neurological disorders with significant unmet medical needs, has announced important…

Read MoreSpruce Biosciences Reports Positive FDA Meetings and Advances TA-ERT BLA Submission for Q4 2026

Integrated DNA Technologies Advances DNA Synthesis with Expanded Speed, Complexity and Scale

Integrated DNA Technologies Expands DNA Synthesis Capabilities to Support Genomics Programs Across Scale and Complexity Integrated DNA Technologies (IDT), a Danaher company and global provider of genomics solutions, has announced an expansion of its DNA synthesis capabilities designed to address…

Read MoreIntegrated DNA Technologies Advances DNA Synthesis with Expanded Speed, Complexity and Scale

BioTalent Canada and Montréal InVivo Partner to Strengthen Quebec’s Life Sciences Workforce

BioTalent Canada and Montréal InVivo Strengthen Partnership to Expand Life Sciences Workforce Development BioTalent Canada and Montréal InVivo have announced an expanded partnership designed to strengthen workforce development across Canada’s life sciences and health technology (LSHT) sector. As part of…

Read MoreBioTalent Canada and Montréal InVivo Partner to Strengthen Quebec’s Life Sciences Workforce

bioAffinity Technologies and AvMEDICAL Sign Nationwide Federal Distribution Agreement for CyPath® Lung

bioAffinity Technologies Expands Government Healthcare Reach Through Distribution Agreement with AvMEDICAL for CyPath Lung bioAffinity Technologies, Inc., a biotechnology company focused on developing noninvasive diagnostic solutions for the early detection of lung cancer and other pulmonary diseases, has announced a…

Read MorebioAffinity Technologies and AvMEDICAL Sign Nationwide Federal Distribution Agreement for CyPath® Lung

Ingenia Therapeutics Lists on KOSDAQ to Advance Next-Generation Vascular Antibody Pipeline

Ingenia Therapeutics Begins KOSDAQ Trading to Advance Vascular-Targeted Therapy Pipeline Ingenia Therapeutics, a clinical-stage biotechnology company focused on developing next-generation vascular-targeted therapies, has announced that its shares have begun trading on South Korea’s KOSDAQ market, marking a significant milestone in…

Read MoreIngenia Therapeutics Lists on KOSDAQ to Advance Next-Generation Vascular Antibody Pipeline

Radiation Detection Company Launches Radiant to Enhance Real-Time Safety in High-Exposure Clinical Settings

Radiation Detection Company Launches Radiant Real-Time Dosimetry Solution to Enhance Radiation Safety in Medical Settings Radiation Detection Company (RDC), a long-established provider of occupational radiation dosimetry services, has announced the launch of Radiant, a real-time electronic dosimetry solution designed to…

Read MoreRadiation Detection Company Launches Radiant to Enhance Real-Time Safety in High-Exposure Clinical Settings

Enhertu® Shows Significant Progression-Free Survival Benefit in First-Line HER2-Mutant Advanced NSCLC in DESTINY-Lung04 Trial

Enhertu Demonstrates Significant Progression-Free Survival Benefit in First-Line HER2 Mutant Metastatic NSCLC Daiichi Sankyo and AstraZeneca have announced positive topline results from the Phase 3 DESTINY-Lung04 trial, demonstrating that Enhertu® (trastuzumab deruxtecan) significantly improved progression-free survival (PFS) compared with the…

Read MoreEnhertu® Shows Significant Progression-Free Survival Benefit in First-Line HER2-Mutant Advanced NSCLC in DESTINY-Lung04 Trial

EMA Validates Pfizer and Valneva’s Marketing Application for Lyme Disease Vaccine Candidate

EMA Validates Pfizer and Valneva’s Marketing Authorization Application for Lyme Disease Vaccine Candidate Pfizer Inc.and Valneva SE have announced an important regulatory milestone for their investigational Lyme disease vaccine candidate, PF-07307405, after the European Medicines Agency (EMA) validated the companies’…

Read MoreEMA Validates Pfizer and Valneva’s Marketing Application for Lyme Disease Vaccine Candidate

biomodal Launches duet mosaic to Deliver Greater Insights from Every Liquid Biopsy Blood Draw

biomodal Launches duet mosaic Workflows to Unlock More Biological Signals from Every Liquid Biopsy Sample biomodal, an omics-focused life sciences technology and analytics company, has announced the launch of its new duet mosaic family, a portfolio designed to help researchers…

Read Morebiomodal Launches duet mosaic to Deliver Greater Insights from Every Liquid Biopsy Blood Draw